UroGen Pharma press release (URGN): Q2 GAAP EPS of -$0.28 in-line. – Revenue of $72.5M (+199.6% Y/Y) beats by $8.96M. – Cash, Cash Equivalents and Marketable Securities: As of June 30, 2026, cash, cash equivalents and marketable securities totaled $108.0 million. – 2026
Urogen Pharma GAAP EPS of -$0.28 In-line, Revenue of $72.5m Beats by $8.96m; Updates FY Outlook
UroGen Pharma press release (URGN): Q2 GAAP EPS of -$0.28 in-line. - Revenue of $72.5M (+199.6% Y/Y) beats by $8.96M. - Cash, Cash Equivalents and Marketable Securities: As of June 30, 2026, cash, cash equivalents and marketable securities totaled $108.0 million. - 2026